Finch Therapeutics Group (FNCH) Competitors $12.75 -0.25 (-1.92%) As of 11:02 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. FBRX, ENTX, TCRX, IGMS, VRCA, CABA, EPIX, ZURA, IPA, and QNCXShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Forte Biosciences (FBRX), Entera Bio (ENTX), TScan Therapeutics (TCRX), IGM Biosciences (IGMS), Verrica Pharmaceuticals (VRCA), Cabaletta Bio (CABA), ESSA Pharma (EPIX), Zura Bio (ZURA), ImmunoPrecise Antibodies (IPA), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors Forte Biosciences Entera Bio TScan Therapeutics IGM Biosciences Verrica Pharmaceuticals Cabaletta Bio ESSA Pharma Zura Bio ImmunoPrecise Antibodies Quince Therapeutics Finch Therapeutics Group (NASDAQ:FNCH) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Is FNCH or FBRX more profitable? Finch Therapeutics Group's return on equity of -69.14% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Forte Biosciences N/A -149.15%-114.25% Do institutionals and insiders believe in FNCH or FBRX? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer FNCH or FBRX? Forte Biosciences has a consensus price target of $61.00, indicating a potential upside of 478.20%. Given Forte Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Forte Biosciences is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer FNCH or FBRX? In the previous week, Forte Biosciences had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Forte Biosciences and 1 mentions for Finch Therapeutics Group. Forte Biosciences' average media sentiment score of 1.29 beat Finch Therapeutics Group's score of 1.14 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Finch Therapeutics Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, FNCH or FBRX? Finch Therapeutics Group has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.97, suggesting that its share price is 197% more volatile than the S&P 500. Which has preferable earnings and valuation, FNCH or FBRX? Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.45Forte BiosciencesN/AN/A-$35.48M-$16.29-0.65 SummaryForte Biosciences beats Finch Therapeutics Group on 9 of the 13 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.48M$209.58M$5.61B$9.11BDividend YieldN/AN/A5.24%4.01%P/E Ratio-1.45N/A27.9620.25Price / SalesN/A253.11430.8999.65Price / CashN/A22.4437.4658.16Price / Book0.896.158.045.49Net Income-$74.75M-$96.61M$3.18B$250.27M7 Day Performance-2.49%12.62%3.72%4.78%1 Month Performance-6.93%9.04%3.72%7.20%1 Year Performance837.50%9.39%29.92%17.27% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics Group1.8095 of 5 stars$12.75-1.9%N/A+858.6%$20.48MN/A-1.45190Positive NewsFBRXForte Biosciences3.5226 of 5 stars$12.48-1.3%$61.00+388.8%+56,027.5%$83.28MN/A-0.775Positive NewsOptions VolumeGap DownENTXEntera Bio2.7047 of 5 stars$1.78-2.7%$10.00+461.8%+1.9%$83.18M$180K-6.8520TCRXTScan Therapeutics3.612 of 5 stars$1.70+17.2%$7.80+358.8%-69.8%$82.06M$2.82M-1.56100IGMSIGM Biosciences4.6162 of 5 stars$1.33-1.5%$5.50+313.5%-80.6%$80.70M$2.68M-0.41190Positive NewsVRCAVerrica Pharmaceuticals4.505 of 5 stars$0.86+3.8%$8.00+828.2%-88.6%$76.77M$7.57M-0.7240News CoverageGap DownCABACabaletta Bio2.586 of 5 stars$1.51+1.3%$14.43+855.5%-77.9%$75.61MN/A-0.5950EPIXESSA Pharma1.9678 of 5 stars$1.71+0.6%$2.00+17.0%-66.6%$75.46MN/A-2.7150Positive NewsZURAZura Bio2.9338 of 5 stars$1.20+9.1%$14.33+1,094.4%-61.9%$75.21MN/A-1.713News CoveragePositive NewsGap UpIPAImmunoPrecise Antibodies3.0921 of 5 stars$1.76+8.0%$4.00+127.3%+69.4%$74.60M$18.16M-1.5280Positive NewsUpcoming EarningsGap DownQNCXQuince Therapeutics3.3605 of 5 stars$1.61-1.2%$8.00+396.9%+147.2%$74.11MN/A-1.1660 Related Companies and Tools Related Companies FBRX Alternatives ENTX Alternatives TCRX Alternatives IGMS Alternatives VRCA Alternatives CABA Alternatives EPIX Alternatives ZURA Alternatives IPA Alternatives QNCX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FNCH Stock Alerts